Paul Reider - 20 Jan 2025 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Reporting relationship: Chief Commercial Officer
Issuer ticker: CHRS
Reported as of: 20 Jan 2025
Net transaction value: -$6,753
SEC form: 4
Accepted by SEC: 22 Jan 2025, 19:49:54 UTC
Prior SEC filing: 07 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Bryan McMichael, as Attorney-in-Fact for Paul Reider

Key filing fact

Paul Reider filed Form 4 for Coherus BioSciences, Inc. (CHRS) on 22 Jan 2025.

Key facts

This page summarizes Paul Reider's Form 4 filing for Coherus BioSciences, Inc. (CHRS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 Jan 2025, 19:49.

Change

Previous filing in this sequence was filed on 07 Jan 2025.
Current net transaction value: -$6,753.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CHRS transaction

Common Stock

Tax liability

Transaction value: $6,753
Shares: -4,858
Change %: -5.6%
Price: $1.39
Shares after: 82,069
Date: 20 Jan 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction.